

Siemens Medical Solutions USA, Inc. % Mr. Andrew Turner Regulatory Affairs Specialist 40 Liberty Boulevard, Mailcode 65-1A MALVERN PA 19355

March 31, 2021

Re: K203443

Trade/Device Name: MAGNETOM Vida, MAGNETOM Sola, MAGNETOM Lumina,

MAGNETOM Altea with syngo MR XA31A

Regulation Number: 21 CFR 892.1000

Regulation Name: Magnetic resonance diagnostic device

Regulatory Class: Class II Product Code: LNH, LNI, MOS

Dated: February 26, 2021 Received: March 1, 2021

Dear Mr. Turner:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for

devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/training-and-continuing-education/cdrh-learn) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

For

Thalia T. Mills, Ph.D.

Director

Division of Radiological Health

OHT7: Office of In Vitro Diagnostics

and Radiological Health

Office of Product Evaluation and Quality

Center for Devices and Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2023 See PRA Statement below.

510(k) Number (if known)

K203443

MAGNETOM Vida, MAGNETOM Sola, MAGNETOM Lumina, MAGNETOM Altea with syngo MR XA31A

Indications for Use (Describe)

Your MAGNETOM system is indicated for use as a magnetic resonance diagnostic device (MRDD) that produces transverse, sagittal, coronal and oblique cross sectional images, spectroscopic images and/or spectra, and that displays the internal structure and/or function of the head, body, or extremities. Other physical parameters derived from the images and/or spectra may also be produced. Depending on the region of interest, contrast agents may be used. These images and/or spectra and the physical parameters derived from the images and/or spectra when interpreted by a trained physician yield information that may assist in diagnosis.

Your MAGNETOM system may also be used for imaging during interventional procedures when performed with MR compatible devices such as in-room displays and MR Safe biopsy needles.

Type of Use (Select one or both, as applicable)	
Prescription Use (Part 21 CFR 801 Subpart D)	Over-The-Counter Use (21 CFR 801 Subpart C)

This section applies only to requirements of the Paperwork Reduction Act of 1995.

This section applies only to requirements of the Faperwork Reduction Act of 1996.

CONTINUE ON A SEPARATE PAGE IF NEEDED.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

FORM FDA 3881 (6/20) Page 1 of 1 PSC Publishing Services (301) 443-6740 E



Section 5 510(k) Summary

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of the Safe Medical Devices Act 1990 and 21 CFR § 807.92.

1. General Information

Establishment: Siemens Medical Solutions USA, Inc.

40 Liberty Boulevard Mail Code 65-1A

Malvern, PA 19355, USA Registration Number: 2240869

Date Prepared: March 29, 2021

Manufacturer: Siemens Healthcare GmbH

Henkestr. 127 91052 Erlangen

Germany

Registration Number: 3002808157

Siemens Shenzhen Magnetic Resonance LTD.

Siemens MRI Center

Hi-Tech Industrial park (middle)

Gaoxin C. Ave., 2nd

Shenzhen 518057, P.R. CHINA Registration Number: 3004754211

2. Contact Information


Andrew Turner

Regulatory Affairs Technical Specialist Siemens Medical Solutions USA, Inc.

40 Liberty Boulevard Mail Code 65-1A

Malvern, PA 19355, USA Phone: (610) 850-5627 Fax: (610) 448-1787

E-mail: andrew.turner@siemens-healthineers.com





3. Device Name and Classification

Device/ Trade name: MAGNETOM Vida, MAGNETOM Sola, MAGNETOM

Lumina, MAGNETOM Altea with syngo MR XA31A

Classification Name: Magnetic Resonance Diagnostic Device (MRDD)

Classification Panel: Radiology

CFR Code: 21 CFR § 892.1000

Classification:

Product Code: Primary: LNH

Secondary: LNI, MOS

4. Legally Marketed Predicate Device

Trade name: MAGNETOM Vida

510(k) Number: K192924

Classification Name: Magnetic Resonance Diagnostic Device (MRDD)

Classification Panel: Radiology

CFR Code: 21 CFR § 892.1000

Classification:

Product Code: Primary: LNH

Secondary: LNI, MOS

5. Intended Use

The indications for use for the subject devices are the same as the predicate device:

Your MAGNETOM system is indicated for use as a magnetic resonance diagnostic device (MRDD) that produces transverse, sagittal, coronal and oblique cross sectional images, spectroscopic images and/or spectra, and that displays the internal structure and/or function of the head, body, or extremities. Other physical parameters derived from the images and/or spectra may also be produced. Depending on the region of interest, contrast agents may be used. These images and/or spectra and the physical parameters derived from the images and/or spectra when interpreted by a trained physician yield information that may assist in diagnosis.

Your MAGNETOM system may also be used for imaging during interventional procedures when performed with MR compatible devices such as in-room displays and MR Safe biopsy needles.

6. Device Description

MAGNETOM Vida, MAGNETOM Sola, MAGNETOM Lumina, MAGNETOM Altea with software *syngo* MR XA31A includes new and modified hardware and software compared to the predicate device, MAGNETOM Vida with software



syngo MR XA20A. A high-level summary of the new and modified hardware and software is provided below:

Hardware

New Hardware

- The **Nexaris Dockable Table** is a new variant of the MR patient table which is used for intraoperative or interventional imaging. It enables the patient transfer between OR tables and the MR system without repositioning on the MR patient table and vice versa during interventional procedures and surgeries. Additionally, it can be used for diagnostic imaging.
- The **Nexaris Head Frame** holds up to two Ultra Flex Large 18 coils. It can be used for head imaging in combination with the Nexaris Dockable Table when the patient is positioned on the transfer board but not pinned in a head clamp.
- New Computer

New Coils

- The **Nexaris Spine 36** is used in combination with and without transfer board for body imaging on the Nexaris Dockable Table.
- The **Flex Loop Large** local coil is a 1Ch receive only multipurpose coil. Modified Hardware
- The **Beat Sensor** is a contact less method for generating **cardiac triggers** as an alternative to the already existing ECG or pulse triggers. It is based on a measurement of the modulation of a weak magnetic Pilot Tone, caused by conformation changes in conductive tissues.

Software

New Features and Applications

- **SVS_EDIT** is a special variant of the SVS_SE pulse sequence type, which acquires two different spectra (one with editing pulses on resonance, one with editing pulses off resonance) within a single sequence.
- BEAT_FQ_nav allows the user to make use of navigator echo based respiratory gating for flow imaging to acquire 4D flow data. Both navigator echo based respiratory gating as well as flow imaging are part of the predicate device already. New is merely the combination of both.
- The HASTE_interactive pulse sequence type extends the existing HASTE pulse sequence type by offering the possibility to interactively change imaging parameters.
- GRE_WAVE is a special variant of the GRE pulse sequence type which allows larger acceleration factors, measuring one or two contrasts. GRE Wave results in higher signal-to-noise ratio for larger acceleration factors which can be leveraged to allow fast high-resolution 3D susceptibilityweighted imaging.
- The Prostate Dot Engine provides an assisted and guided workflow for prostate imaging. This automated workflow leads to higher reproducibility of



- slice angulation and coverage; this may support exams not having to be repeated.
- Injector coupling is a software application that allows the connection of certain contrast agent injectors to the MR system for simplified, synchronized contrast injection and examination start.

Modified Features and Applications

- An optimized high bandwidth inversion recovery pulse is combined with gradient echo readout to improve diagnostic image quality when imaging myocardial tissue.
- The **AbsoluteShim** mode is a shimming procedure based on a 3-echo gradient echo protocol.
- Deep Resolve Sharp is an interpolation algorithm based on trained convolutional neuronal networks which increases the perceived sharpness of the interpolated images.
- Deep Resolve Gain is a reconstruction option which improves the SNR of the scanned images
- The **3D ASL sequence (tgse_asl)** now provides relCBF maps, by implementing an additional M0 scan and performing the corresponding reconstruction method. It also provides BAT maps in multiple inversion time(multi-TI) imaging.

Other Modifications and / or Minor Changes

- **Elastography-Addln** synchronizes settings between the Elastography sequence and the active driver.
- **HASTE MoCo** is an image-based motion correction in the average-dimension for the HASTE pulse sequence type.
- The **Needle Intervention AddIn** provides a user interface for workflow improvement of MR-guided needle interventions under real-time imaging conditions. It supports planning a needle trajectory, laser-based localization of the entry point as well as automatic slice positioning.
- The PhaseRev Dot Addin/Component supports the measurement workflow of the user by automatically flipping the direction of the phase encoding gradient.
- Coil independent pulse sequences remove the coil information from the pulse sequences and generate this information during run-time from automatic coil detection and localization.
- The adjustment mode "**offcenter**" triggers a transmitter adjustment method that is specialized for offcenter imaging. The transmitter adjustment determines the RF voltage that is required to excite a certain B1 field.



7. Substantial Equivalence

MAGNETOM Vida, MAGNETOM Sola, MAGNETOM Lumina, MAGNETOM Altea with software *syngo* MR XA31A are substantially equivalent to the following predicate device:

Predicate Device	 Product Code	Manufacturer
MAGNETOM Vida with syngo MR XA20A		Siemens Healthcare GmbH

MAGNETOM Vida, MAGNETOM Sola, MAGNETOM Lumina, MAGNETOM Altea with software *syngo* MR XA31A include hardware and software already cleared on the following reference devices:

Reference Devices	FDA Clearance Number and Date	Product Code	Manufacturer
MAGNETOM Sola with	K192496, cleared February	LNH	Siemens Healthcare
syngo MR XA20A	28, 2020	LNI, MOS	GmbH
MAGNETOM Lumina with	K192924, cleared March	LNH	Siemens Healthcare
syngo MR XA20A	11, 2020	LNI, MOS	GmbH
MAGNETOM Altea with	K192496, cleared February	LNH	Siemens Healthcare
syngo MR XA20A	28, 2020	LNI, MOS	GmbH
MAGNETOM Area,	K202014, cleared	LNH	Siemens Healthcare
MAGNETOM Skyra,	September 08, 2020	LNI, MOS	GmbH
MAGNETOM			
Prisma/Prisma ^{fit} with syngo			
MR XA30A			

8. Technological Characteristics

The subject devices, MAGNETOM Vida, MAGNETOM Sola, MAGNETOM Lumina, MAGNETOM Altea with software *syngo* MR XA31A, are substantially equivalent to the predicate device with regard to the operational environment, programming language, operating system and performance.

The subject devices conform to the standard for medical device software (IEC 62304) and other relevant IEC and NEMA standards.

As seen above there are some differences in technological characteristics between the subject devices and predicate device, including different hardware and modified software. These differences have been tested and the conclusions from the non-clinical data suggests that the features bear an equivalent safety and performance profile to that of the predicate device.

9. Nonclinical Tests

The following performance testing was conducted on the subject devices.



Performance Test	Tested Hardware or Software	Source/Rationale for test
Sample clinical images	coils, new and modified software features	Guidance for Submission of Premarket Notifications for
Image quality assessments by sample clinical images. In some cases a comparison of the image quality / quantitative data was made.	- comparison images between the new / modified features and the predicate device features	Magnetic Resonance Diagnostic Devices
Performance bench test	mainly new and modified hardware	
Software verification and validation	mainly new and modified software features	Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices
Biocompatibility	surface of applied parts	ISO 10993-1
Electrical safety and electromagnetic compatibility (EMC)	Only separate testing for Nexaris Dockable Table	IEC 60601-1-2

The results from each set of tests demonstrate that the devices perform as intended and are thus substantially equivalent to the predicate device to which it has been compared.

10. Clinical Tests / Publications

No additional clinical tests were conducted to support substantial equivalence for the subject devices; however, as stated above, sample clinical images were provided. Clinical publications were referenced to provide information on the use of the following features and functions.

Feature / Function	Clinical Publication
SVS_EDIT	[1] Mescher et al, NMR Biomed 11, 266–272 (1998)
	[2] Mikkelsen et al, Neurolmage 159, 32-45 (2017)
	[3] Saleh et al, Neurolmage 189, 425–431 (2019)
GRE_WAVE	[4] B. Bilgic et al., "Wave-CAIPI for Highly Accelerated 3D Imaging."
	MRM 73(6):2152-2162 (2015)
	[5] F. Breuer et al., Controlled aliasing in volumetric parallel imaging (2D
	CAIPIRINHA)." MRM 55(3):549-56 (2006)
	[6] Essner M, Zinsser D, Kündel M, et. al. Performance of an Automated
Prostate Dot Engine	Workflow for Magnetic Resonance Imaging of the Prostate: Comparison
	With a Manual Workflow. Invest Radiol. 2020 May;55(5):277-284. Doi:
	10.1097.
	[7] Horger W, Thoermer G, Weiland E, et. al. Prostate Dot Engine – a
	system guided and assisted workflow to improve consistency in prostate
	MR exams.



	[8] Yadong C, Siyuan H, Chunmei Li, et. al. Performance and Reproducibility of a Day Optimizing Throughput (Dot) Workflow Engine in Automated Prostate MRI Positioning. Abstract accepted for the 28th annual meeting of the International Society of Magnetic Resonance in Medicine (ISMRM).
Deep Resolve Gain	[9] Kellman P. et al. Image Reconstruction in SNR Units: A General Method for SNR Measurement. MRM 2005; 54:1439. Erratum in MRM 2007; 58:311. [10] Blu T. et al. The SURE-LET approach to image denoising. IEEE
	Transactions on Image Processing 16(11):2778-86
Improvement of TGSE_ASL	[11] D C. Alsop, J A. Detre, et al. Recommended Implementation of Arterial Spin Labeled Perfusion MRI for Clinical Applications: A consensus of the ISMRM Perfusion Study Group and the European Consortium for ASL in Dementia. Magn Reson Med. 2015 Jan; 73(1): 102–116.
	[12] R B. Buxton, L R. Frank, et al. A general kinetic model for quantitative perfusion imaging with arterial spin labeling. Magn Reson Med. 1998 Sep; 40(3):383-96.
	[13] S. Yang, B. Zhao, et al. Improving the Grading Accuracy of Astrocytic Neoplasms Noninvasively by Combining Timing Information with Cerebral Blood Flow: A Multi-TI Arterial Spin-Labeling MR Imaging Study. Am. J. Neuroradiol. 2016 Dec; 37 (12) 2209-2216
	[14] P G Qiao, C Han, et al. Clinical assessment of cerebral hemodynamics in Moyamoya disease via multiple inversion time arterial spin labeling and dynamic susceptibility contrast-magnetic resonance imaging: A comparative study. J Neuroradiol. 2017 Jul;44(4):273-280.
	[15] Y Shen, B Zhao, et al. Cerebral Hemodynamic and White Matter Changes of Type 2 Diabetes Revealed by Multi-TI Arterial Spin Labeling and Double Inversion Recovery Sequence. Front Neurol. 2017; 8: 717.

11. Safety and Effectiveness

The device labeling contains instructions for use and any necessary cautions and warnings to ensure safe and effective use of the device.

Risk Management is ensured via a risk analysis in compliance with ISO 14971, to identify and provide mitigation of potential hazards early in the design cycle and continuously throughout the development of the product. Siemens Healthcare GmbH adheres to recognized and established industry standards, such as the IEC 60601-1 series, to minimize electrical and mechanical hazards. Furthermore, the device is intended for healthcare professionals familiar with and responsible for the acquisition and post processing of magnetic resonance images.

MAGNETOM Vida, MAGNETOM Sola, MAGNETOM Lumina, MAGNETOM Altea with software *syngo* MR XA31A conform to the following FDA recognized and international IEC, ISO and NEMA standards:



Recognition Number	Product Area	Title of Standard	Reference Number and date	Standards Development Organization
19-4	General II (ES/ EMC)	C1:2009/(R)2012 and A2:2010/(R)2012 (Consolidated Text) Medical electrical equipment - Part 1: General requirements for basic safety and essential performance (IEC 60601-1:2005, MOD)	ES60601- 1:2005/(R)2012 and A1:2012	ANSI AAMI
19-8	General II (ES/ EMC)	Medical electrical equipment - Part 1-2: General requirements for basic safety and essential performance - Collateral Standard: Electromagnetic disturbances - Requirements and tests	60601-1-2 Edition 4.0 2014-02	IEC
12-295	Radiology	Medical electrical equipment - Part 2-33: Particular requirements for the basic safety and essential performance of magnetic resonance equipment for medical diagnosis	60601-2-33 Ed. 3.2 b:2015	IEC
5-40	General I (QS/ RM)	Medical devices - Application of risk management to medical devices	14971 Second edition 2007-03-01	ISO
5-114	General I (QS/ RM)	Medical devices - Part 1: Application of usability engineering to medical devices	62366-1:2015	ANSI AAMI IEC
13-79	Software/ Informatics	Medical device software - Software life cycle processes [Including Amendment 1 (2016)]	62304:2006/A1:201 6	ANSI AAMI IEC
12-232	Radiology	Acoustic Noise Measurement Procedure for Diagnosing Magnetic Resonance Imaging Devices	MS 4-2010	NEMA
12-288	Radiology	Standards Publication Characterization of Phased Array Coils for Diagnostic Magnetic Resonance Images	MS 9-2008 (R2014)	NEMA
12-300	Radiology	Digital Imaging and Communications in Medicine (DICOM) Set 03/16/2012 Radiology	PS 3.1 - 3.20 (2016)	NEMA
2-220	Biocompati bility	Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process	10993- 1:2009/(R)2013	ANSI AAMI ISO





12. Conclusion as to Substantial Equivalence

MAGNETOM Vida, MAGNETOM Sola, MAGNETOM Lumina, MAGNETOM Altea with software *syngo* MR XA31A have the same intended use and same basic technological characteristics than the predicate device system, MAGNETOM Vida with *syngo* MR XA20A, with respect to the magnetic resonance features and functionalities. While there are some differences in technical features compared to the predicate device, the differences have been tested and the conclusions from all verification and validation data suggest that the features bear an equivalent safety and performance profile to that of the predicate device and reference devices.

Siemens believes that MAGNETOM Vida, MAGNETOM Sola, MAGNETOM Lumina, MAGNETOM Altea with software *syngo* MR XA31A are substantially equivalent to the currently marketed device MAGNETOM Vida with software *syngo* MR XA20A (K192924, cleared on March 11, 2020).